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complex targets it is not surprising that patient specific quality control is considered essential for safe 
delivery. Given the variety of targets and clinical scenarios we employ different strategies for different 
patients to ensure that the most important aspects of the treatment are appropriately tested, be it steep 
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Abstract. Stereotactic Ablative Body Radiotherapy (SABR) is an extension of the concepts of 
Stereotactic Radiosurgery from intracranial procedures to extracranial targets. This brings with 
it new technological challenges for set-up of a SABR program and continuing quality assurance. 
Compared with intracranial procedures SABR requires consideration of motion and 
inhomogeneities and has to deal with a much larger variety of targets ranging from lung to liver, 
kidney and bone. To meet many of the challenges virtually all advances in modern radiotherapy, 
such as Intensity Modulated and Image Guided Radiation Therapy (IMRT and IGRT) are used. 
Considering the few fractions and high doses per fraction delivered to complex targets it is not 
surprising that patient specific quality control is considered essential for safe delivery. Given the 
variety of targets and clinical scenarios we employ different strategies for different patients to 
ensure that the most important aspects of the treatment are appropriately tested, be it steep dose 
gradients, inhomogeneities or the delivery of dose in the presence of motion. The current paper 
reviews the different approaches and phantoms utilised at Peter MacCallum Cancer Centre for 
SABR QA. 
1. Introduction 
Stereotactic Ablative Body Radiotherapy (SABR) is a relatively novel approach to cancer treatment 
where very high doses per fraction are given to small lesions using image guidance and motion 
management. SABR has become an accepted treatment modality for early stage lung cancer [1] and an 
increasing number of other curative and palliative indications [2]. Compared to conventional 
radiotherapy SABR features a number of challenges that require consideration for quality assurance: 
 
 Doses exceeding 10Gy per fraction 
 Small and possibly dynamic radiation fields 
 Non-coplanar beam arrangements 
 Inhomogeneity correction 
 Assessment of motion during planning 
 Motion management during treatment 
 High quality and frequent image guidance 
MMND&ITRO2016 IOP Publishing
Journal of Physics: Conference Series 777 (2016) 012017 doi:10.1088/1742-6596/777/1/012017
Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution
of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.







1.1 Typical SABR scenarios  
Based on the intracranial experience, the ‘classical’ SABR scenario 
is a small lesion located in a large parallel-organised critical 
structure such as lung and liver. Compared to conventional 
radiotherapy SABR dose distributions are often not homogenous 
with high dose regions exceeding 125% of prescription dose being 
not uncommon. Tight margins around the target are normal as 
image guidance allows for target localisation directly prior to 
treatment [3-7]. An extension of this concept is intrafraction 
monitoring of tumour location, which can either be done with 
radiobeacons [8, 9] or intrafraction kilovoltage monitoring (KIM) 
[10]. 
 Figure 1 illustrates typical SABR scenarios. In the case of 
scenario a) the objective is to constrain the dose closely to the target 
and conformity indices become an important planning tool. The 
scenarios shown in figure 1b are emerging in clinical problems such 
as prostate SABR and the treatment of vertebral metastases on the 
left side of the figure and lesions close to intestines or other dose 
limiting structures on the right. Here steep dose gradients are 
important where for quality assurance spatial resolution becomes more important than absolute dose 
accuracy. Table 1 provides a summary of SABR scenarios and their specific challenges form a 
dosimetric point of view. 
 
1.2. Patient specific quality assurance 
Given these considerations SABR requires both machine and patient specific quality control (QC) 
activities to ensure SABR is delivered as planned. We report here on a suite of phantoms and QC 
approaches that were developed specifically for patient specific SABR QC at our institution. 
2. Materials and Methods 
A risk analysis was performed 
prior to commencing a SABR 
program for early stage lung 
cancer at Peter MacCallum 
Cancer Centre in 2009. As 
motion, small fields and 
inhomogeneity were 
considered key concerns, a 
Modus Quasar phantom which 
includes lung inhomogeneities 
was modified to allow for 
various motion patterns (figure 
2) [11]. 
 The phantom was used 
for individual patient QC in 
our institution [12] as well as 
credentialing of a clinical trial 
of lung SABR (CHISEL, TROG 09.02). For the latter inhomogeneity correction was tested using small 
fields and the effect of motion was studied using radiochromic film [13]. It is well suited for assessment 
of dose distributions in coronal or sagittal plane as the cylinder holding dosimeters (right in figure 2b) 
can be rotated around a sup/inf axis. However, in some SABR applications the dose distribution in axial 
 
Figure 1. SABR scenarios a) 
‘classical’ stereotactic problem, 




Figure 2. The modified QUASAR phantom (Modus Medical) 
featuring inhomogeneities and a programmable motor that allows 












plane is required to demonstrate the steep dose gradients between target dose and spinal cord and 
oesophagus. For this purpose we designed a phantom to mimic the body of a patient with the particular 
aim to verify the steep dose gradients encountered in SABR of vertebral lesions. This phantom is shown 
in figure 3. 
  




Main challenges Planning considerations QC approach, 
Phantom/dosimetry 
Lung: early stage 
curative intent 
Inhomogeneity, 
motion, small fields 
Energy <=10MV, Field size 
> 3 x 3cm2, no VMAT FFF 
for single fraction 
4DCT review, complex cases 







As above, limitations on 
non-coplanar to limit 
overlap 
As above 
Liver Motion, contrast CT, 
IGRT 
Gating or breath hold 
considered 
4DCT review, IGRT strategy 
review 




4DCT review, in vivo 
dosimetry for skin 
Bone metastases Irregular size, close to 
skin (eg sternum) 
Consider electron 
contribution 
Consider in vivo dosimetry 
for skin 
Vertebral body Steep dose gradients 
required 
IMRT > 9 fields 
VMAT 
Phantom measurement using 
Rod (Figure 3) 
Prostate Irregular motion, 
urethra in centre 




Quality Control activities for 
individual patients depend on 
the scenario. Some important 
ones are listed in table 1. In 
addition to this we can utilise 
an independent dose 
calculation tool, Mobius 3D 
and FX. The latter relies on 
MLC dynalog files to 
determine dose distribution in 




While the introduction of 
motion did not alter the QC 
results in the phantom, the 
introduction of 
inhomogeneities as shown in 
figure 2, did. The initial 
measurements for individual patients confirmed that the Analytical Anisotropic Algorithm (AAA) used 
in the Varian Eclipse planning system has difficulties to predict the dose behind inhomogeneities 
accurately [15, 16]. After the initial phase of measurements this is now only verified using an 
independent monitor unit calculation and general checks of the treatment planning system.  
 
Figure 3. The ‘Rod’ phantom for SABR spine QA measurements. The 
evaluation relies largely on radiochromic film but can also include ion 
chambers and TLD measurements. 
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 Given the fact that 3D conformal treatments could in general be verified without any significant 
problems once the treatment couch had been taken into consideration, patient specific QC activities have 
been reduced [12]. However, in the context of SABR for vertebral lesions, where Intensity Modulated 
Radiation Therapy is essential, every patient treatment is still verified using physical measurements prior 
to treatment. For this an ionisation chamber measurement and a radiochromic film assessment in the 
“Rod” phantom shown in figure 3 is routinely performed. It is particularly the dose distribution recorded 
on the film as shown in figure 3 on the right which informs the acceptability of the plan. The steep dose 
gradient in both plan and treatment verification film can be clearly seen and a 1mm distance to 
agreement criterion is typically used for evaluation. 
4. Discussion and Conclusion 
For the wide variety of SABR applications no single phantom appears to be suitable for individual 
patient QC as different treatment approaches require visualisation of dose distributions in different 
planes with high spatial resolution. In addition to ionisation chambers measurements radiochromic film 
was found to be essential for most of the measurements. Future work will be directed to studying real 
time dosimeters with high spatial resolution such as the dose magnifying glass [17] as replacement to 
shorten the turn around time for QC measurements. 
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